Evidence map›Paper›PMID 28875990›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ

Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe, Mohini Ranganathan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Douglas L BoggsDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Jacques D NguyenDepartment of Neuroscience; The Scripps Research Institute, La Jolla, CA, USA.
Daralyn MorgensonVA Connecticut Healthcare System, West Haven, CT, USA.
Michael A TaffeDepartment of Neuroscience; The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-9827-1738
Mohini RanganathanDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are >550 chemical compounds and >100 phytocannabinoids isolated from cannabis, including Δ

Indexed as

AnimalsCannabidiolCannabinoid Receptor AgonistsDronabinolDrug InteractionsHumansCannabidiolCannabinoid Receptor AgonistsDronabinol

Identifiers

PMID28875990
PMCPMC5719112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.